08 Tuberculosis

  • Definition: Tuberculosis (TB) is a highly contagious infection primarily caused by the bacterium Mycobacterium tuberculosis, which predominantly targets the lungs but can also affect other vital organs, including the kidneys, spine, and brain. Understanding TB's pathophysiology is crucial, as it involves a complex interaction between the bacteria and the host's immune response.

  • Transmission: TB is chiefly transmitted through the inhalation of airborne droplets. When a person with active TB coughs, sneezes, talks, or even laughs, they expel microscopic droplets containing the bacteria. These droplets can remain suspended in the air for considerable periods, especially in inadequately ventilated enclosed spaces, significantly elevating the risk of transmission to individuals nearby.

  • Airborne Duration: The chance of contracting TB is heightened in environments with poor air circulation. The bacteria can persist in the air for hours, thus necessitating stringent infection control measures in places such as hospitals, clinics, and correctional facilities.

Infection Prevention Strategies

  • N95 Respirator Masks: Utilizing N95 respirator masks is essential for healthcare personnel and anyone in close proximity to TB patients, as these masks effectively filter out small airborne particles, thereby significantly reducing the likelihood of inhaling infectious agents.

  • Powered Air Purifying Respirators: These battery-operated respirators offer advanced protection by filtering airborne contaminants and are particularly beneficial for individuals in high-risk settings.

  • Isolation Protocol: Patients diagnosed with active TB must be placed in isolation within single occupancy rooms designed with negative pressure ventilation systems. This procedure is critical to minimizing the risk of spreading infectious airborne droplets to surrounding areas, thereby safeguarding healthcare providers and visitors.

Stages of TB Infection

  • Latent TB:

    • In this state, the immune system manages to contain the bacteria. As a result, infected individuals do not exhibit symptoms and generally display normal chest x-rays, highlighting the importance of screening to identify at-risk individuals.

    • While latent TB is not contagious, there exists a 5-10% lifetime risk of reactivation into active TB, with higher susceptibility noted in people with compromised immune systems, such as those with HIV or those undergoing immunosuppressive therapy.

  • Active TB:

    • At this stage, the immune system fails to contain the bacteria, leading to noticeable symptoms and increased transmissibility. Common symptoms include a persistent cough lasting more than three weeks, hemoptysis (coughing up blood), fever, night sweats, chills, general weakness, and unexplained weight loss. These symptoms necessitate immediate medical evaluation and testing.

    • In patients with active TB, chest x-rays typically reveal infiltrates, cavities, or nodules that can aid in diagnosis and monitoring disease progression.

Treatment Considerations

  • Latent TB Treatment:

    • The primary goal of treatment for latent TB is to prevent the progression to active disease. Commonly used regimens include:

    • Isoniazid (INH) and Rifapentine administered once weekly for 12 weeks under directly observed therapy. This regimen is preferred due to its shorter duration and enhanced adherence rates.

    • Daily treatment may also include a combination of INH + Rifampin for 3 months or Rifampin alone for a duration of 4 months.

    • Alternatively, INH alone can be prescribed daily for 6 or 9 months, particularly in cases where there is concern about potential drug interactions or patient compliance.

  • Active TB Treatment:

    • Treatment for active TB is typically administered in two phases:

    • Initial Phase: This phase involves a treatment regimen known as RIPE (Rifampin, Isoniazid, Pyrazinamide, Ethambutol) for a minimum of 2 months. This intensive phase is critical for rapidly reducing the bacterial load.

    • Continuation Phase: Following the initial phase, treatment transitions to Rifampin and Isoniazid for a minimum of 4 additional months. This duration may be adjusted based on the results of drug susceptibility testing, which checks for possible drug resistance.

Development of TB Tests

  • Screening for Latent TB:

    • Routine screening is strongly recommended for individuals who have had close contact with TB patients or for those at elevated risk for infection, including individuals living with HIV, those who have undergone organ transplants, and those with chronic lung conditions.

    • Testing Methods: The commonly used tests for latent TB include:

    • Interferon-gamma release assays (IGRAs): These blood tests measure the immune response to specific TB antigens, helping to determine latent TB infection status.

    • The Tuberculin skin test (PPD): This involves intradermal administration of purified protein derivative, with assessment of a delayed-type hypersensitivity reaction indicating possible TB infection.

  • Positive Results:

    • Positive results from skin tests or IGRAs are assessed based on the degree of induration, which varies depending on individual risk factors:

    • >5 mm for immunocompromised individuals,

    • >10 mm for those with a higher risk of exposure, and

    • >15 mm for individuals considered low risk.

Diagnosing Active TB

  • Symptoms: Key symptoms indicative of active TB include a prolonged cough (lasting three weeks or more), hemoptysis, persistent fever, night sweats, and unintended weight loss. Such indicators warrant thorough evaluation and prompt testing.

  • Diagnostic Tests:

    • Confirmatory tests include a positive tuberculin skin test or IGRA result and chest x-ray imaging that may show signs of consolidation or cavitation in the lungs.

    • Additionally, sputum cultures are crucial for identifying Acid-Fast Bacilli (AFB), enabling definitive diagnosis and appropriate management.

Key Medications and Side Effects

  • Rifampin:

    • Side Effects: Notable adverse effects include hepatotoxicity, hemolytic anemia, and orange-red discoloration of urine and other body fluids. Patients should be educated about these effects, particularly the aesthetic changes, which can cause concern.

    • Drug Interactions: As a potent inducer of CYP450 enzymes, Rifampin can significantly affect the metabolism of various medications, particularly those used in HIV treatment and anticoagulant therapies, necessitating careful management.

  • Isoniazid (INH):

    • Side Effects: Common side effects include hepatotoxicity, peripheral neuropathy (which can be alleviated by administering vitamin B6), and drug-induced lupus erythematosus. Ongoing monitoring of liver function tests is essential during treatment.

    • Contraindications: INH should be avoided in individuals with acute liver disease or those who have demonstrated severe allergic reactions to the drug.

  • Pyrazinamide:

    • Side Effects: This medication can lead to elevated serum uric acid levels, increasing the risk of gout. Patients may also experience gastrointestinal side effects and malaise, which could affect adherence.

  • Ethambutol:

    • Side Effects: Ethambutol is particularly noted for its potential to induce optic neuritis, leading to visual disturbances. Regular visual examinations are necessary, along with monitoring for possible confusion or disorientation in some patients.

Conclusion of TB Overview

  • Effective management of tuberculosis necessitates a comprehensive understanding of infection control measures, adherence to treatment protocols, monitoring for potential adverse effects, and regular assessment of liver function tests associated with medications used in therapy. Attention must be given to the distinct treatment regimens for latent versus active TB to ensure the prevention of disease reactivation and to control the spread within communities.